160 related articles for article (PubMed ID: 30380865)
1. Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester.
Castro-Falcón G; Seiler GS; Demir Ö; Rathinaswamy MK; Hamelin D; Hoffmann RM; Makowski SL; Letzel AC; Field SJ; Burke JE; Amaro RE; Hughes CC
J Med Chem; 2018 Dec; 61(23):10463-10472. PubMed ID: 30380865
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
3. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
4. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
5. Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry.
Masson GR; Maslen SL; Williams RL
Biochem J; 2017 May; 474(11):1867-1877. PubMed ID: 28381646
[TBL] [Abstract][Full Text] [Related]
6. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
8. A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR.
Ran T; Lu T; Yuan H; Liu H; Wang J; Zhang W; Leng Y; Lin G; Zhuang S; Chen Y
J Mol Model; 2012 Jan; 18(1):171-86. PubMed ID: 21523553
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
10. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
[TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.
Good DW; George T; Watts BA
J Biol Chem; 2008 Sep; 283(39):26602-11. PubMed ID: 18660503
[TBL] [Abstract][Full Text] [Related]
12. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
13. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
Yang S; Xiao X; Meng X; Leslie KK
PLoS One; 2011; 6(10):e26343. PubMed ID: 22039466
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
17. Discovery and assembly-line biosynthesis of the lymphostin pyrroloquinoline alkaloid family of mTOR inhibitors in Salinispora bacteria.
Miyanaga A; Janso JE; McDonald L; He M; Liu H; Barbieri L; Eustáquio AS; Fielding EN; Carter GT; Jensen PR; Feng X; Leighton M; Koehn FE; Moore BS
J Am Chem Soc; 2011 Aug; 133(34):13311-3. PubMed ID: 21815669
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
19. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
[TBL] [Abstract][Full Text] [Related]
20. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
